Acalabrutinib (Tablets) Monotherapy. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Acalabrutinib (Tablets) Monotherapy, 2023, version number 1a, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/840-acalabrutinib-tablets-monotherapy.pdfRegulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy. | 3 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Acalabrutinib | |
| Sensitivity (+) | TP53 deletion | Chronic Lymphocytic Leukemia | Acalabrutinib | |
| Sensitivity (+) | 17p deletion | Chronic Lymphocytic Leukemia | Acalabrutinib |